Gilead Sciences announced positive results from its Phase 3 IDEAL trial for Livdelzi (seladelpar) in primary biliary cholangitis (PBC), showing statistically significant normalization of alkaline phosphatase (ALP) levels. These findings, observed in patients with inadequately controlled disease, further support Livdelzi's efficacy and safety profile, complementing previous Phase 3 RESPONSE data. The company plans to present the full data at an upcoming medical congress and engage with global regulatory authorities.

On Semiconductor Corporation's stock has reached an all-time high of $129.17, with a remarkable 184% increase over the past year. Despite its elevated P/E ratio, 27 analysts have revised earnings upwards, indicating continued optimism. This surge is attributed to strong investor confidence and the company's strategic position in the growing semiconductor industry.

Kenvue Canada and Fuel Transport have initiated a pilot program, "Electric Loop (eLoop)," to test electric freight delivery on urban routes in the Greater Toronto Area. This collaboration aims to assess the performance, energy efficiency, and emissions impact of electric vehicles in real-world conditions, including dense city routes and colder weather. The initiative is a practical step towards lower-emissions logistics and helps both companies understand the role of electric delivery vehicles in shaping more efficient, sustainable supply chains.

BMO Capital has reiterated an Outperform rating for Boston Properties Inc. (NYSE:BXP) with a $68.00 price target, citing continued leasing momentum in Q2 2026 expected to drive occupancy growth. The firm's analysis follows an investor dinner with Boston Properties executives who discussed strong performance, including Q1 2026 EPS of $0.64, significantly surpassing forecasts. Other analysts, Truist Securities and Piper Sandler, offered varied outlooks, with Piper Sandler highlighting increased demand from AI and finance sectors in key markets.

Maxim Group reduced its price target on Lucid Diagnostics Inc. (NASDAQ:LUCD) from $3 to $2, while maintaining a Buy rating, following the company's weaker-than-expected first-quarter 2026 revenue report of $1.3 million. Despite the revenue miss and a GAAP net loss of $23.6 million, the company is actively pursuing commercialization strategies in anticipation of Medicare reimbursement approval and reported $27.9 million in cash and equivalents. The firm specializes in early detection of esophageal precancer, but the article suggests that AI stocks might offer greater returns.

LENSAR Inc (Nasdaq: LNSR) reported a 9% year-over-year increase in recurring revenue for Q1 2026, reaching $12.6 million, which accounted for approximately 94% of total sales. This shift towards a more repeatable revenue base is a key focus for investors, with MarketBeat listing a consensus price target of $10.00 for the stock. The company specializes in laser-based ophthalmic surgery systems, and its quarterly revenue mix is closely watched as an indicator of its commercial profile and execution in the cataract-surgery platform business.

The Paychex Small Business Jobs Index improved for the third consecutive month in May 2026, reaching its highest level in the current year. This indicates increased job growth among U.S. small businesses, with 14 of the top 20 largest states and 15 of the top 20 largest metros reporting an increase. Additionally, weekly earnings growth continued to rise, and weekly hours worked showed positive growth for the third consecutive month.

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Stride, Inc. (LRN) and its officers. The firm is encouraging stockholders who purchased Stride securities before October 22, 2024, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis for class action lawsuits.

IGC Pharma announced the addition of Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. With approximately 80% of targeted participants having completed the trial, the company is moving toward database lock and topline analysis. This expansion aims to enhance patient access, data integrity, and disciplined execution as the trial nears completion.

IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a new clinical site for its Phase 2 CALMA trial of IGC-AD1, which targets agitation in Alzheimer's disease. With approximately 80% of targeted participants having completed the trial, the study is advancing towards database lock and topline analysis. This addition aims to support final-stage execution, patient access, and data integrity as the trial progresses.